Sex: U
Vaccine: COVID19, UNK
Symptoms: Thrombosis
Clinical narrative: Blood clots from COVID Vaccine/Can you please repeat the product name; Eliquis; This is a spontaneous report from a non-contactable consumer based on information received by Pfizer from pharmaceutical (manufacturer control number US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-068891), license party for apixaban (ELIQUIS).  This case was received via Pfizer Inc (Reference number: 2021883671) on 12-Jul-2021 and was forwarded to BMS on 13-Jul-2021. This subject of an unknown age and gender was enrolled in a phase IV study titled "A non-solicited program in which a patient received a BMS product" (Protocol: CV185-NON-SOLICITED-OTHER STUDIES). The subject received APIXABAN. The report describes a case of THROMBOSIS (Blood clots). Co-suspect products included BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, batch/lot number unknown) as dose number unknown, single for COVID-19 immunisation. On an unknown date, the subject started APIXABAN (unknown route), (unspecified dose and frequency). On an unknown date, the subject experienced THROMBOSIS (seriousness criterion medically significant). The action taken with APIXABAN(Unknown) was unknown. At the time of the report, THROMBOSIS outcome was unknown. For APIXABAN(Unknown), the reporter did not provide any causality assessments.   pharmaceutical Medical Evaluation Comment: This patient who was on apixaban therapy had blood clots . Based on the limited information regarding the suspect therapy details, event onset details, medical history it cannot be ascertained with reasonable possibility that apixaban contributed to the reported event  Follow-up (13Jul2021): This is a follow-up spontaneous report from a non-contactable consumer based on information received by Pfizer from Bristol-Myers Squibb (manufacturer control number US-BRISTOL-MYERS SQUIBB COMPANY-BMS-2021-068891), license party for apixaban (ELIQUIS).  This case was initially received via Pfizer Inc (Reference number: 2021883671) on 12-Jul-2021. The most recent information was received on 13-Jul-2021 and was forwarded to BMS on 14-Jul-2021. This subject of an unknown age and gender was enrolled in a phase IV study titled "A non-solicited program in which a patient received a BMS product" (Protocol: CV185-NON-SOLICITED-OTHER STUDIES). The subject received APIXABAN. The report describes a case of THROMBOSIS (Blood clots). Co-suspect products included Covid-19 Vaccine for COVID-19 immunisation. On an unknown date, the subject started APIXABAN (unknown route), (unspecified dose and frequency). On an unknown date, the subject experienced THROMBOSIS (seriousness criterion medically significant). The action taken with APIXABAN(Unknown) was unknown. At the time of the report, THROMBOSIS outcome was unknown. Consumer initially reported blood clots from Covid Vaccine but then consumer reported Eliquis and then confirmed Eliquis by saying yes. For APIXABAN(Unknown), the reporter did not provide any causality assessments. Most recent follow-up information received on 13-Jul-2021, from the consumer incorporated above included: Narrative updated. pharmaceutical Medical Evaluation Comment: This patient had blood clots after receiving apixaban study therapy. Based on the limited information available regarding the therapy details, event onset date, action taken with the suspect and outcome of the event, it cannot be ascertained with the reasonable possibility that the apixaban could have contributed to the event thrombosis.  pharmaceutical Medical Evaluation Comment: This patient had blood clots after receiving apixaban study therapy. Based on the limited information available regarding the therapy details, event onset date, action taken with the suspect and outcome of the event, it cannot be ascertained with the reasonable possibility that the apixaban could have contributed to the event thrombosis.  No follow-up attempts are possible, information about batch/lot number cannot be obtained.; Sender's Comments: pharmaceutical Medical Evaluation Comment: This patient had blood clots after receiving apixaban study therapy. Based on the limited information available regarding the therapy details, event onset date, action taken with the suspect and outcome of the event, it cannot be ascertained with the reasonable possibility that the apixaban could have contributed to the event thrombosis.